| Revenue growth | 29.4% CAGR FY21-26 |
|---|---|
| Margins | 19.4% adj. EBITDA margin |
| Order book | Pipeline 17% higher YoY |
| Demand visibility | Strong; sustained 12-15 year drug lifecycles |
| Management confidence | High; pipeline up 17% entering FY27 |
Growth
FY26 revenue grew at 29.4% CAGR (FY21-26); top-20 client revenue tripled since FY21.
Outlook
Targeting multi-billion enterprise status; pipeline entering FY27 is 17% higher than previous year.
Risks
Structural shift in Sales & Marketing centralization; competition from IT scalers and traditional agencies.
Earnings Call filed with NSE, NSE: INDGN. Summary written with AI assistance from the document.
Indegene Ltd: key numbers
- Share price
- ₹596.30
- Market cap
- ₹14,366 Cr
- Revenue (annual)
- ₹3,510 Cr
- Net profit (annual)
- ₹401.1 Cr
- P/E (TTM)
- 35.8×Sector 53.1×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 9.92%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indegene Ltd
All →Indegene Business Update
Indegene Limited hosted its Indegene Digital Summit 2026, focusing on operationalizing AI within life sciences. The event also featured the presentation of the VITAL Awards 2026.
Indegene Merger & Restructuring
Indegene Limited completed the internal merger of its two indirect wholly owned subsidiaries in Germany. This reorganization does not impact Indegene's financial position or operations.
Indegene Legal & Regulatory
Indegene Limited received preliminary court approval for a class action settlement related to the U.S. Telephone Consumer Protection Act. Final hearing is scheduled for January 2027.
Indegene Legal & Regulatory
The U.S. Court preliminarily approved the class action settlement for Indegene's subsidiary. The maximum settlement fund is approximately ₹44.84 Crore.
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary, Indegene Inc., finalized a class-action settlement framework regarding U.S. fax communication violations. The maximum potential settlement fund is USD 4.72 million (₹44.84 Crore).
- Value
- ₹44.84 Cr
Indegene Legal & Regulatory
Indegene Limited's subsidiary finalized a USD 4.72 million class-action settlement agreement regarding U.S. TCPA violations. The settlement, involving approximately 18,851 unique fax numbers, remains subject to court approval.
- Value
- ₹45.24 Cr